CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) — Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal Virome platform, today announced it was granted the U.S. Patent No. 11,446,344. The patent, granted to Flagship Pioneering, is exclusively licensed to Ring Therapeutics.

The patent covers anellovirus vectors that can be used to deliver a variety of therapeutic modalities. This patent builds on an earlier patent (US Patent No. 11,166,996) issued November 2021 on methods for delivering a therapeutic polypeptide or nucleic acid by administering Anellovector™ compositions.

“Ring has extensively pioneered a new class of viral vectors by creating a scientific understanding of anelloviruses through our research and publications,” said Tuyen Ong, MD, MBA, Chief Executive Officer of Ring Therapeutics. “This patent grant supports the novelty of the Anellogy™ platform and our unique approach to harnessing the human commensal vioma to develop life-saving therapies and ultimately redefine what’s possible in programmable medicine.”

Avak Kahvejian, Ph.D., General Partner of Flagship Pioneering and Co-Founder and Chairman of Ring, added, “This is another example of Flagship Pioneering companies pursuing science at the frontiers of human biology to create new solutions for humankind Developing Anellovectors™ as a broad bioplatform that could be applicable across diseases is extremely promising to open up the field of genetic medicine.”

About Ring Therapeutics

Ring Therapeutics is revolutionizing the field of gene therapy and nucleic acid medicine by harnessing the most abundant and diverse member of the human commensal vioma, anelloviruses. The Company has developed the Anellogy™ platform, which focuses on anelloviruses to potentially treat a wide range of diseases. By harnessing the unique properties of these commensal viruses, the Anellogy™ platform can…